The effects of dosage variation in black seed cumin oil (Nigella sativa L.) use on HbA1c levels and interleukin-17A expression in patients at risks of metabolic syndrome
DOI:
https://doi.org/10.12928/pharmaciana.v9i2.8055Keywords:
Keywords, Metabolic Syndrome, BCSO, HbA1c, IL-17AAbstract
Metabolic syndrome causes an imbalance of the immune system and increased levels of HbA1c and IL-17A expression. Black cumin seed oil (BCSO) is known to have antioxidant and immunomodulatory  properties. This study reports the effects of dosage variation in BCSO (1.5 and 3 ml per day for 20 days) on HbA1c levels and IL-17A expression in patients at risk of metabolic syndrome at Jetis 1 Public Health Center in Bantul, Yogyakarta. It employed a crossover design in which a total of 66 patients at risk of metabolic syndrome were divided into two groups receiving a sequence of different treatments. Group 1 (N=33) received treatment A first, which was BCSO at a dose of 1.5 ml/day for 20 days. Then, after a washout period of 7 days, it received treatment B, 3 ml of BCSO per day for 20 days. Group 2 followed the same procedure only vice versa, treatment B, then A. The HbA1c levels were measured by the mean plasma glucose (MPG) method, while the IL-17A expression was detected by flow cytometry. The average HbA1c level and IL-17A expression of the treatment groups were statistically analyzed with 95% confidence level. In response to the treatment regime, the HbA1c level of group 1 was 7.34 ± 2.51% (a decrease), and that of group 2 was 7.72 ± 2.44% (an increase). The IL-17 expression in group 1 was 3.74 ± 3.52% (a decrease), and the one in group 2 was 4.07 ± 3.65% (an increase). The effects of administering 1.5 ml and 3 ml BCSO per day for 20 consecutive days on Hb1c level (p=0.17) and IL-17A expression (p=0.67) were not significantly different. Most patients experience a decrease in HbA1c levels and IL-17A expression after the treatment. Insignificant differences between the two groups mean that at the doses of 1.5 ml/day and 3 ml/day for 20 days, BCSO exhibits the same effects in patients at risk of metabolic syndrome registered at Jetis 1 Public Health Center in Bantul, Yogyakarta.
References
Ahmad, A., Husain A., Mujeeb M., Khan., Najmi A.K., Siddique N.A., Damanhouri Z.A., Anwar F., 2013, A Review On Therapeutic Potential Of Nigella Sativa: A Miracle Herb, Asian Pacific Journal of Tropical Biomedicine, 3(5): 337-352.
American Diabetes Association., 2017, Standards of Medical Care in Diabetes: Promoting Health and Reducing Disparities in Populations, Diabetes Care, 40 (1): S6-S10.
Andaloussi, AB., Martinean, LC., Spor D., Vuong T., Leduc, C., Joly E., 2008, Antidiabetic Activity Of Nigella Sativa Seed Extract In Cultured Pancreatic-Î’ Cells, Skeletal Muscle Cells And Adipocytes. Pharmaceutical Biology Journals, 46(1-2): 96-104.
Andrew, S.P., Van Belle, T., Wurster, A.L., Suto A., Michaud, M., Zhang, D., Grusby, M.J., Herrath, M.V, 2009, Interleukin-21 Is Required For The Development Of Type I Diabetes In NOD Mice, Diabetes, 58(5):1144-1155.
Anggraeni, D., 2007, Mewaspadai Adanya Sindrom Metabolic. (Online).
(Retrieved from http://labcito.co.id. on December 24, 2016).
Ansari, Z.M., Mohammad, N., Rahat, A.K., Shahzad, F.H, 2017, Protective Role Of Nigella Sativa In Diabetic Nephropathy: A Randomized Clinical Trial, Saudi Journal of Kidney Diseases and Transplantation, 28(1):9-14.
Bamosa, A.O., Kaatabi, H., Lebdaa, F.M., Elq A.M., Al-Sultanb A., 2010, Effect Of Nigella Sativa Seeds On The Glycemic Control Of Patients With Type 2 Diabetes Mellitus, Indian journal of physiology and pharmacology, 54(4):344-54.
Cohen, Joseph M., 2014, Top 27 Scientific Health Benefits of the Panacea Black
Cumin Seed (Nigella sativa), Retrieved on September 24, 14:27 WIB
De Carvalho, V.F., Bressan, J., Babio, N., Salas-Salvado, J., 2013, Prevalence Of Metabolic Syndrom In Brazilian Adults: A Systematic Review, BMC Public Health, 13:1198.
Dandona, P., Aljada, A., Chaudhuri, A., Mohanty, P., Garg, R., 2005, Metabolic Syndrome: A Comprehensive Perspective Based On Interaction Between Obesity And Diabetes, Circulation, 111(11):1448-1454.
Dehkordi, F.R, and A.F. Kamkhah., 2008, Antihypertensive Effect Of Nigella Sativa L. Seed Extract In Patients With Mild Hypertension, Fundam Clin Pharmacol, 22(4):447-452.
Fallah H.H., Amini M., Mohtashami R., Gramarchehre M. E., 2013, Blood Pressure Lowering Effect Of Niglle Sativa L. Seed Oil In Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Phytother Res, 27(12): 1849-1853.
Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., Shimomura, I., 2004, Increased Oxidative Stress In Obesity And Its Impact On Metabolic Syndrome, The Journal of Clinical Investigation, 114(12):1752-1761.
Geistanger, A, Arends S, Berding C., 2008, Statistical Methods For Monitoring The
Relationship Between The IFCC Reference Measurement Procedure For
Hemoglobin A1c And The Designated Comparison Method In The United
States, Japan, Sweden. Clinical Chemistry, 54(8):1379-85.
Heshmati, J., Namazi, N., 2015, Effects of black seed (Nigella sativa) on metabolic parameters in diabetes mellitus: a systematic review, Complementary Therapies Medicine, 23(2):275-282.
Hosseini, M.S., Mirkarimi, S.A., Amini, M., Mohtashami, R., Kianbakht, S., Fallah, Hosseini H., 2013, Effects Of Nigella Sativa L. Seed In Type II Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Medicinal Plants, 12(47): 93-99.
International Diabetes Federation., 2006,The IDF Consensus Worldwide Defenition of the Metabolic Syndrome, (online) (www.idf.org) 25 September 2017: 14:27, Indonesia.
Islam, Muhammad, T., 2016, Biological activities and therapeutic promises of Nigella sativa L., International journal of pharma sciences and scientific research, Departement of pharmacy Southern University Bangladesh, Bangladesh, 2(6): 242-243.
Jaarin, K., Foong, W.D., Yeoh, M.H., Kamarul, Z.Y.N., Qodriyah, H.M.S, Azman, A., Zuhair, J.S.F, Juliana, A.H., Kamisah, Y., 2015, Mechanisms Of The Antihypertensive Effects Of Nigella Sativa Oil In L-Name- Induce Hypertensive Rats, Clinics: 70 (11):751-757.
Kern, PA, Ranganathan S, Li C, Wood L, Ranganathan G., 2001, Adipose Tissue
Tumor Necrosis Factor And Interleukin-6 Expression In Human Obesity And
Insulin Resistance. American Journal of Physiology-Endocrinology and Metabolism, 280 (5): 745-751.
Keyhanmanesh, R., Saadat, S., Mohammadi, M., Shahbazfar, A.A., Fallahi, M., 2015, The Protective Effect of α-Hederin, the Active Constituent of Nigella sativa, on Lung Inflammation and Blood Cytokines in Ovalbumin Sensitized Guinea Pigs, 29(11):1761-1767.
Kumar, N.P., George, P.J., Kumaran, P., Dolla, C.K., Nutman, T.B., Babu, S., 2014, Diminished Systemic And Antigen-Specific Type 1, Type 17, And Other Proinflammatory Cytokines In Diabetic And Prediabetic Individuals With Latent Mycobacterium Tuberculosis Infection, The Journal of Infectious Diseases, 210(10):1670-1678.
Mohtashami, A., Mohammad, H.E., 2016, Effects Of Nigella Sativa Supplementation On Blood Parameters And Anthropometric Indices In Adults: A Systematic Review On Clinical Trials, Journal of Research in Medical Sciences, 7(04): 213-219.
Nady, S., Hoover, J.I., Shata., Mohamed, T., 2009, Interleukin-12 Is the Optimum Cytokine To Expand Human Th17 Cells In Vitro, Clinical and Vaccine Immunology: 16(6): 798-805.
Najmi, A, Nasiruddin, M., Khan, R.A., Haque, S.F., 2012, Therapeutic Effect Of NS (Nigella Sativa L.) In Patients Of Poor Glycemic Control, Asian Journal of Pharmaceutical and Clinical Research, 5:224-228.
Nathan, D.M., Kuenen, J., Borg, R., 2008, A1C-Derived Average Glucose Study
Group. Translating the A1C Assay into Estimated Average Glucose
Values. Diabetes Care, 31: 1473-1478.
Novak, M., Bjorck, L., Welin, C., Manhem, K.., Rosengren, A., 2013, Gender Differences In The Prevalence Of Metabolic Syndrome In 50-Year-Old Swedish Men And Women With Hypertension Born In 1953, Journal of Human Hypertension, 27(1): 56-61.
Rahmatini., 2010, Evaluasi Khasiat Dan Keamanan Obat (Uji Klinik), Majalah
Kedokteran Andalas, 1(34) : 31-38.
Randhawa, M.A., Al-Ghamdi, M.S., 2002, A Review Of The Pharmaco-Therapeutic Effects Of Nigella Sativa, Pakistan Journal of Medical Research, 41 (2): 77-83.
Smeltzer, suzanne C., Barebrenda G., 2002, Buku Ajar Keperawatan Medikal
Bedah Brunner dan Suddarth (Ed.8, Vol.1,2) EGC: Jakarta.
Soegondo, 2008. Hidup Secara Mandiri dengan Diabetes Melitus, Kencing Manis,
Sakit Gula, FK UI, Jakarta.
Stehouwer, C. D., Henry, R. M., Ferreira, I., 2008, Arterial Stiffness In Diabetes
And The Metabolic Syndrome: A Pathway To Cardiovascular Disease,
Diabetologia, 51(4):527-539.
Zareian, P., Dizgah, I.M., 2014, Serum Interleukin 17 in Type 2 Diabetes Mellitus, Journal of Archives in Military Medicine, 2(4):e24689.
Downloads
Published
Issue
Section
License
Authors who publish with Pharmaciana agree to the following terms:
- Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
1.png)
